Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Feb 2022 07:00 AM
RNS
Dose escalation in the phase I trial of AVA6000
31 Jan 2022 04:41 PM
RNS
Second Price Monitoring Extn
31 Jan 2022 04:36 PM
RNS
Price Monitoring Extension
18 Jan 2022 07:00 AM
RNS
Second pre|CISION Pro-drug Candidate Selected
12 Jan 2022 02:05 PM
RNS
Second Price Monitoring Extn
12 Jan 2022 02:00 PM
RNS
Price Monitoring Extension
10 Jan 2022 07:00 AM
RNS
Update on AffiDX and detection of Omicron variant
04 Jan 2022 11:06 AM
RNS
Second Price Monitoring Extn
04 Jan 2022 11:01 AM
RNS
Price Monitoring Extension
22 Dec 2021 04:26 PM
RNS
Issue of Equity and Total Voting Rights
22 Dec 2021 11:05 AM
RNS
Second Price Monitoring Extn
22 Dec 2021 11:00 AM
RNS
Price Monitoring Extension
22 Dec 2021 07:00 AM
RNS
AffiDX Receives CE Mark for Consumer Self-Testing
16 Dec 2021 07:00 AM
RNS
Issue of Equity and Total Voting Rights
15 Dec 2021 07:00 AM
RNS
Change of auditor
15 Dec 2021 07:00 AM
RNS
AffiDx® lateral flow test detects Omicron variant
29 Nov 2021 07:00 AM
RNS
FDA Approval of IND Application for AVA6000
18 Nov 2021 04:41 PM
RNS
Second Price Monitoring Extn
18 Nov 2021 04:36 PM
RNS
Price Monitoring Extension
02 Nov 2021 07:00 AM
RNS
Update on UK Availability of AffiDX Test
14 Oct 2021 04:36 PM
RNS
Price Monitoring Extension
14 Oct 2021 12:36 PM
RNS
Issue of Equity and Total Voting Rights
30 Sep 2021 07:00 AM
RNS
Interim Results for the Period Ended 30 June 2021
29 Sep 2021 07:00 AM
RNS
Development Milestone in LG Chem Partnership
22 Sep 2021 04:41 PM
RNS
Second Price Monitoring Extn
22 Sep 2021 04:35 PM
RNS
Price Monitoring Extension
09 Sep 2021 07:00 AM
RNS
Notice of Results
06 Sep 2021 07:00 AM
RNS
New appointments to Scientific Advisory Board
02 Sep 2021 07:00 AM
RNS
Appointment of Chief Scientific Officer
25 Aug 2021 04:40 PM
RNS
Second Price Monitoring Extn
25 Aug 2021 04:35 PM
RNS
Price Monitoring Extension
18 Aug 2021 07:00 AM
RNS
Directorate Change
11 Aug 2021 07:00 AM
RNS
First Patient Dosed in AVA6000 Phase 1 Trial
04 Aug 2021 07:00 AM
RNS
Update on AffiDX Lateral Flow Test
14 Jul 2021 07:00 AM
RNS
Diagnostics achieves ISO 13485 Certification
12 Jul 2021 04:41 PM
RNS
Second Price Monitoring Extn
12 Jul 2021 04:35 PM
RNS
Price Monitoring Extension
29 Jun 2021 07:00 AM
RNS
AffiDX Lateral Flow Test Detects Delta Variant
28 Jun 2021 12:13 PM
RNS
Result of AGM
21 Jun 2021 02:05 PM
RNS
Second Price Monitoring Extn
21 Jun 2021 02:00 PM
RNS
Price Monitoring Extension
21 Jun 2021 07:00 AM
RNS
AffiDX Lateral Flow Test Distribution Agreement
15 Jun 2021 08:00 AM
RNS
Issue of Equity and Total Voting Rights
11 Jun 2021 02:05 PM
RNS
Second Price Monitoring Extn
11 Jun 2021 02:00 PM
RNS
Price Monitoring Extension
11 Jun 2021 11:07 AM
RNS
Registration of AffiDX Lateral Flow Test in EU
09 Jun 2021 09:08 AM
RNS
Holding(s) in Company
07 Jun 2021 07:00 AM
RNS
MHRA Confirms Registration of Lateral Flow Test
01 Jun 2021 07:00 AM
RNS
Update on Lateral Flow Test Regulatory Submissions
28 May 2021 07:00 AM
RNS
Response to speculation

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100